Testosterone Treatment Outcomes with Topical Gel versus Injectable Testosterone Undecamoate on Metabolic Syndrome and Sexual Function

The objective of this study was to observe the dose response effects of testosterone (T) treatment on symptoms of sexual dysfunction and the metabolic syndrome.Two cohorts of elderly men with late-onset hypogonadism were followed over 9 months.Group 1, consisting of 28 men (mean age, 61 years; mean T level, 2.07+-0.50ng/mL), received long-acting T undecanoate (TU; 1000 mg); Group 2, composed of 27 men (mean age, 60 years; mean T level, 2.24 +-0.41 ng/mL), received T gel (50 mg/day) for 9 months.In patients treated with T gel, plasma T levels rose from 2.24 +-0.41 to 2.95 +-0.52 (statistically significant) at 3 months, 3.49 +-0.89 (statistically significant) at 6 months, and 3.80 +-0.73 ng/mL at 9 months (T level at 6 months was compared with T level at 3 months).With TU, plasma T levels rose from 2.08 +-0.56 to 4.81+-0.83(statistically significant) at 3 months, 5.29 +-0.91 at 6 months, and 5.40 6 0.77 ng/mL at 9 months.With TU, the plasma T levels were statistically higher than with T gel with TU, there was a greater improvement in sexual symptoms and in symptoms of the metabolic syndrome.with both treatments, changes in waist circumference correlated with changes in total, low density, and high-density lipoprotein cholesterol.Parameters of safety were not different between the 2 treatments.T administration had a beneficial effect on sexual dysfunction and symptoms of the metabolic syndrome in elderly men.The higher plasma levels of T generated with TU than with T gel were clearly more effective, indicating that there is a T dose-effect relationship.